|
1
|
Koo SH: Nonalcoholic fatty liver disease:
molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol.
19:210–215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gentile CL and Pagliassotti MJ: The role
of fatty acids in the development and progression of nonalcoholic
fatty liver disease. J Nutr Biochem. 19:567–576. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaila B and Raman M: Obesity: a review of
pathogenesis and management strategies. Can J Gastroenterol.
22:61–68. 2008.PubMed/NCBI
|
|
4
|
Angulo P: Obesity and nonalcoholic fatty
liver disease. Nutr Rev. 65:S57–S63. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marra F, Gastaldelli A, Svegliati Baroni
G, Tell G and Tiribelli C: Molecular basis and mechanisms of
progression of non-alcoholic steatohepatitis. Trends Mol Med.
4:72–81. 2008. View Article : Google Scholar
|
|
6
|
Parekh S and Anania FA: Abnormal lipid and
glucose metabolism in obesity: implications for nonalcoholic fatty
liver disease. Gastroenterology. 132:2191–2207. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gómez-Lechón MJ, Donato MT,
Martínez-Romero A, Jiménez N, Castell JV and O’Connor JE: A human
hepatocellular in vitro model to investigate steatosis. Chem Biol
Interact. 165:106–116. 2007.PubMed/NCBI
|
|
8
|
Ricchi M, Odoardi MR, Carulli L, et al:
Differential effect of oleic and palmitic acid on lipid
accumulation and apoptosis in cultured hepatocytes. J Gastroenterol
Hepatol. 24:830–840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stapleton D, Mitchelhill KI, Gao G, et al:
Mammalian AMP-activated protein kinase subfamily. J Biol Chem.
271:611–614. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Misra P: AMP activated protein kinase: a
next generation target for total metabolic control. Expert Opin
Ther Targets. 12:91–100. 2008.PubMed/NCBI
|
|
11
|
Viollet B, Mounier R, Leclerc J, Yazigi A,
Foretz M and Andreelli F: Targeting AMP-activated protein kinase as
a novel therapeutic approach for the treatment of metabolic
disorders. Diabetes Metab. 33:395–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saha AK, Avilucea PR, Ye JM, Assifi MM,
Kraegen EW and Ruderman NB: Pioglitazone treatment activates
AMP-activated protein kinase in rat liver and adipose tissue in
vivo. Biochem Biophys Res Commun. 314:580–585. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park JC, Hur JM, Park JG, Kim SC, Park JR,
Choi SH and Choi JW: Effects of methanol extract of Cirsium
japonicum var. ussuriense and its principle,
hispidulin-7-O-neohesperidoside on hepatic alcohol-metabolizing
enzymes and lipid peroxidation in ethanol-treated rats. Phytother
Res. 18:19–24. 2004. View
Article : Google Scholar
|
|
14
|
Clark JM, Brancati FL and Diehl AM:
Nonalcoholic fatty liver disease. Gastroenterology. 122:1649–1657.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ruhl CE and Everhart JE: Epidemiology of
nonalcoholic fatty liver. Clin Liver Dis. 8:501–519. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ha SK, Kim J and Chae C: Role of
AMP-activated protein kinase and adiponectin during development of
hepatic steatosis in high-fat diet-induced obesity in rats. J Comp
Pathol. 145:88–94. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Federico A, Niosi M, Vecchio Blanco CD and
Loguercio C: Emerging drugs for nonalcoholic fatty liver disease.
Expert Opin Emerg Drugs. 13:145–158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Viollet B, Foretz M, Guigas B, et al:
Activation of AMP-activated protein kinase in the liver: a new
strategy for the management of metabolic hepatic disorders. J
Physiol. 574:41–53. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee WJ, Kim M, Park HS, et al: AMPK
activation increases fatty acid oxidation in skeletal muscle by
activating PPARalpha and PGC-1. Biochem Biophys Res Commun.
340:291–295. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lagouge M, Argmann C, Gerhart-Hines Z, et
al: Resveratrol improves mitochondrial function and protects
against metabolic disease by activating SIRT1 and PGC-1alpha. Cell.
127:1109–1122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang ZQ, Zhang XH, Yu Y, et al:
Artemisia scoparia extract attenuates non-alcoholic fatty
liver disease in diet-induced obesity mice by enhancing hepatic
insulin and AMPK signaling independently of FGF21 pathway.
Metabolism. 62:1239–1249. 2013. View Article : Google Scholar
|
|
22
|
Quan HY, Kim do Y, Kim SJ, Jo HK, Kim GW
and Chung SH: Betulinic acid alleviates non-alcoholic fatty liver
by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling
pathway. Biochem Pharmacol. 85:1330–1340. 2013. View Article : Google Scholar : PubMed/NCBI
|
